• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q filed by Kiniksa Pharmaceuticals International plc

    4/29/25 4:15:30 PM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KNSA alert in real time by email

    Unavailable

    Get the next $KNSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KNSA

    DatePrice TargetRatingAnalyst
    3/13/2025$40.00Buy
    Citigroup
    9/13/2024$40.00Buy
    Jefferies
    5/3/2024$34.00Overweight
    Wells Fargo
    12/29/2021$37.00 → $34.00Buy
    B of A Securities
    More analyst ratings

    $KNSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

      – Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory disease of the heart that is often underdiagnosed or misdiagnosed – LONDON, April 30, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, has partnered with Country Music Association, Academy of Country Music, and GRAMMY Award-winning country star, Carly Pearce, to share her personal experience with recurrent

      4/30/25 8:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, w

      4/29/25 7:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

      LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and

      4/24/25 4:01:00 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Financials

    Live finance-specific insights

    See more
    • Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, w

      4/29/25 7:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

      LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and

      4/24/25 4:01:00 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Abiprubart development in Sjögren's Disease to be discontinued –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and c

      2/25/25 7:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    SEC Filings

    See more
    • SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

      144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      5/7/25 5:13:12 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

      144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      5/7/25 4:00:34 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Kiniksa Pharmaceuticals International plc

      10-Q - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

      4/29/25 4:15:30 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/14/24 4:32:31 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/14/24 4:15:22 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/13/24 4:30:25 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

      3/13/25 7:43:42 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Jefferies initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

      9/13/24 7:34:05 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Wells Fargo initiated coverage of Kiniksa Pharmaceuticals with a rating of Overweight and set a new price target of $34.00

      5/3/24 11:21:30 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF COMMERCIAL OFFICER Moat Ross exercised 10,122 units of Class A Ordinary Share at a strike of $17.76 and sold $283,416 worth of Class A Ordinary Share (10,122 units at $28.00) (SEC Form 4)

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      5/5/25 4:54:51 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF OPERATING OFFICER Tessari Eben

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      5/5/25 4:53:14 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF ACCOUNTING OFFICER Megna Michael R

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      5/5/25 4:52:19 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care